| 3β-Adiol | 5α-androstane-3β,17β-diol |
| 8β-VE2 | 8-vinylestra-1:3,5 (10)-triene-3,17β-diol |
| AC | adenylate cyclase |
| ACC | adrenocortical cancer |
| ACTH | adrenocorticotropic hormone |
| ADT | androgen deprivation therapy |
| AF-1 | transcriptional activation domain 1 |
| AF-2 | transcriptional activation domain 2 |
| AI | aromatase inhibitors |
| AKR1C1 | aldo-keto reductase family 1 member C1 |
| AKT | protein kinase B |
| ANGII | angiotensin II |
| AR + | androgen receptor positive |
| AR | androgen receptor |
| ARID1A | AT-rich interactive domain-containing protein 1A |
| ATF4 | activating transcription factor 4 |
| ATF6 | activating transcription factor 6 |
| ATM | ataxia telangiectasia |
| AVPC | aggressive variant prostate cancer |
| BC | breast cancer |
| BCL-2 | B-cell lymphoma-2 |
| BCSCs | breast cancer stem cells |
| BH | Bcl-2 homology |
| BH3 | BCL-2 homology 3 |
| BMP | bone morphogenic protein |
| BPA | bisphenol A |
| BPH | benign prostatic hyperplasia |
| BRAF | serine/threonine-protein kinase B-raf |
| BRCA1 | BReast CAncer gene 1 |
| BRCA2 | BReast CAncer gene 2 |
| C/EBPs | CCAAT/enhancer binding proteins |
| Ca2+ | calcium ion |
| cAMP | cyclic adenosine monophosphate |
| CB1 | cyclin B1 |
| CCEC | clear cell carcinoma |
| CCNE1 | cyclin E1 |
| CD1 | cyclin D1 |
| CDH1 | E-cadherin gene |
| CDK4 | cyclin dependent kinase 4 |
| CDKN2A | cyclin dependent kinase inhibitor 2a |
| c-FLIP | FLICE/caspase-8-inhibitory protein |
| CHOP | C/EBP homologous protein |
| CREB | cAMP response element-binding protein |
| CReP | constitutive repressor of eIF2a phosphorylation |
| CRPC | castration resistant PC |
| CTNNB1 | catenin beta 1 |
| CYT C | cytochrome c |
| DHT | dihydrotestosterone |
| DPN | 2:3-bis (4-hydroxyphenyl) propionitrile |
| DR4 or 5 | death receptor 4 or 5 |
| E2 | estradiol |
| EAB | estrogen and androgen blocking |
| EC | endometrial cancer |
| ECM | extracellular matrix |
| EGFR | epidermal growth factor receptor |
| eIF2a | initiation factor 2 alpha |
| EMT | epithelial–mesenchymal transition |
| ER - | ER negative |
| ER | estrogen receptor |
| ER+ | ER positive |
| ERE | estrogen response element |
| ERK | extracellular signal-regulated kinase |
| ERK1/2 | extracellular signal-regulated kinase 1 |
| ERs | estrogen receptors |
| ERS | reticulum endoplasmic stress |
| ERα | estrogen receptor alpha |
| ERβ | estrogen receptor beta |
| ESR1 | estrogen receptor 1 |
| ESR2 | estrogen receptor 2 |
| FADD | Fas-associated protein with death domain |
| FAS | fas cell surface death receptor |
| FASL | FAS ligand |
| FLICE | FADD (Fas-associated death domain)-like IL-1β–converting enzyme |
| C-FLIP | cellular FLICE inhibitory protein |
| FOXL2 | forkhead box protein L2 |
| FOXO3a | forkhead box O3a |
| FSH | follicle-stimulating hormone |
| GADD34 | growth-arrest- and DNA-damage-induced transcript 34 |
| GPCR | G-protein-coupled receptor |
| GPER | G protein-coupled estrogen receptor 1 |
| H3K4me3 | histone H3 trimethylation of lysine 4 |
| H3K9me3 | histone H3 trimethylation of lysine 9 |
| HER2 | human epidermal growth factor receptor 2 |
| Hi-Myc | human c-Myc driven prostate cancer |
| HO-1 | heme oxygenase 1 |
| HRT | hormone replacement therapy |
| IAP | inhibitor apoptosis protein |
| IFITM1 | IFN-induced transmembrane protein 1 |
| IFNα | interferon α |
| IGF1 | insulin like growth factor 2 |
| IGF1R | insulin-like growth factor 1 receptor |
| IGF2 | insulin like growth factor 2 |
| IRE1-α | inositol-requiring protein 1 alpha |
| JAK | janus kinase |
| JNK | c-Jun N-terminal kinase |
| KRAS | kirsten rat sarcoma virus |
| LCT | Leydig cell tumor |
| LH | luteinizing hormone |
| LHRH | luteinizing hormone releasing hormone |
| LTED | long-term estrogen-deprived |
| LPS | lipopolysaccharide |
| MAPK | mitogen-activated protein kinase |
| MEK | MAP kinase kinase |
| MYBL2 | v-myb myeloblastosis viral oncogene homolog (avian)-like 2 |
| MPs | matrix metalloproteinases |
| mTOR | mammalian target of rapamycin |
| MUC1 | mucin 1 |
| N-CoR | nuclear receptor co-repressor 1 |
| NF1 | neurofibromatosis type 1 |
| NF-κB | nuclear factor kappa B |
| NO | nitric oxide |
| OC | ovarian cancer |
| OHT | hydroxytamoxifen |
| PARP-1 | poly (ADP-ribose) polymerase 1 |
| PC | prostate cancer |
| PDGFA | platelet derived growth factor subunit A |
| PERK | protein kinase RNA (PKR)-like endoplasmic reticular (ER) |
| PHTPP | 4-[2-Phenyl-5:7-bis(trifluoromethyl)pyrazolo [1,5-a] pyrimidin-3-yl] phenol |
| PI3K | phoshatidylinositol-3 kinase |
| PKA | protein kinase A |
| PKC | protein kinase C |
| PKG | protein kinase G |
| PLC | phospholipase C |
| POLE | DNA polymerase epsilon, catalytic subunit |
| PPT | 1:3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole |
| PR | progesterone receptor |
| PR-A | progesterone receptor isoform A |
| PR-B | progesterone receptor isoform B |
| PRKAR1A | protein kinase cAMP-dependent regulatory type I alpha |
| PTEN | phosphatase and tensin homolog |
| TFs | transcription factors |
| PUMA | p53 upregulated modulator of apoptosis |
| PXN | paxillin |
| Rb | retinoblastoma protein |
| RLX | raloxifene |
| ROS | reactive oxygen species |
| RPL22 | ribosomal protein L22 |
| SEC | serous carcinoma |
| SERMs | selective ER modulators |
| SFKs | Src family kinases |
| SHBG | sex hormone binding globulin |
| SMRT | silencing mediator of retinoic acid and thyroid hormone receptor |
| STAT | signal transducer and activator of transcription |
| STK11 | serine/threonine kinase 11 |
| SUV39H1 | suppressor of variegation 3-9 homolog 1 |
| SUV39H2 | suppressor of variegation 3-9 homolog 2 |
| TAF9B | TATA-Box Binding Protein Associated Factor 9 |
| TAM | tamoxifen |
| TCs | testicular cancers |
| TERF2 | telomere specific protein 2 |
| TFIID | transcription factor IID |
| TGCTs | testicular germ cell tumors |
| TGFβ1 | transforming growth factor beta-1 |
| TNBC | triple negative breast cancers |
| TNF | tumor necrosis factor |
| TNF-R1 | tumor necrosis factor-receptor 1 |
| TRADD | tumor necrosis factor receptor type 1-associated death domain protein |
| TRAIL | TNF-related apoptosis-inducing ligand |
| TRAIL | TNF-related apoptosis-inducing ligand |
| TRAILR1 or -R2 | TRAIL receptor |
| TUNEL | Terminal deoxynucleotidyl transferase dUTP nick end labeling |
| UCS | endometrial uterine carcinosarcoma |
| UPR | unfolded protein response |
| VEGFA | vascular endothelial growth factor A |